Neurogene
NGNE
NGNE
55 hedge funds and large institutions have $241M invested in Neurogene in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
1.33% less ownership
Funds ownership: 3.35% → 2.01% (-1.3%)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
Holders
55
Holding in Top 10
2
Calls
$777K
Puts
$632K
Top Buyers
| 1 | +$23.7M | |
| 2 | +$20.3M | |
| 3 | +$12.4M | |
| 4 |
O
OrbiMed
New York
|
+$11.1M |
| 5 |
PA
Perceptive Advisors
New York
|
+$6.16M |
Top Sellers
| 1 | -$97.4M | |
| 2 | -$4.45M | |
| 3 | -$1.63M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.15M |
| 5 |
Two Sigma Investments
New York
|
-$650K |